Hims Hers Health Inc株(ISIN: US4330001060)についての詳細は以下をご覧ください。このページの下にある過去データ、チャート、テクニカル分析といったセクションにて詳細を掲載しています。

Truist warned that Hims faces renewed litigation risk after Novo's exit, which could create a prolonged legal overhang on the ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

The loss of Novo’s involvement significantly dented investor confidence in Hims & Hers, plunging shares in the latter by 35% ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

BofA analyst Allen Lutz estimates Hims & Hers’ year-over-year core revenue growth has “slowed sharply,” from about 45% in Q3 of 2024 to 29% in Q1 of 2025, despite a tailwind from shifting customers to ...

Gross profit margins are typically a sign of strong (or weak) pricing power and market share, and a 73% margin tells investors all they need to know. Hims & Hers is an industry leader, and its ...